BGI Halts Revolocity Launch, Cuts Complete Genomics Staff as Part of Strategic Shift | GenomeWeb

NEW YORK (GenomeWeb) – BGI has made "substantial" staff cuts at its Complete Genomics subsidiary in Mountain View, California and has put the commercialization of the Revolocity high-throughput human genome sequencing system on hold, GenomeWeb has learned.

The move is part of a change in strategy that turns Complete Genomics into an R&D organization in support of BGI's products and clinical assays, in particular its recently launched desktop sequencer, BGISEQ-500.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.